Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 887 participants.
Also called NCT02554890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase
- Phase 4
- Enrolled
- 887 participants
- Sponsor
- Registry
-
NCT02554890
-
- Other papers using this trial's data
- Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
- Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial
- Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial
- Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02554890. Randomized; quadruple masking; primary purpose supportive care. Start 2016-04-29 (actual); primary completion 2018-06-29 (actual). Results posted on 2019-09-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
- Acronym
- PIONEER-HF
- Condition
- Acute Heart Failure
- Intervention (Drug)
- sacubitril/valsartan (LCZ696)
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- sacubitril/valsartan (LCZ696) matching placebo
- Intervention (Drug)
- enalapril matching placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02554890- Content hash
492357b6362b7a9ebee07605eb471f59624936d381eda932c5ff1cc58282b20f